News Briefs

EU Expands Indication for Gilead HIV Drug

May 28, 2003

This article is part of The Body PRO's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

On Tuesday, Gilead Science announced it has received authorization from the European Union to expand the indication of its HIV drug Viread in all 15 EU states. With the expansion, Viread is approved for use in combination with other drugs to prevent the duplication of HIV in patients initiating antiretroviral therapy as well as in previously treated patients. The EU's Committee for Proprietary Medicinal Products and the Scientific Committee of the European Medicines Evaluation Agency gave the marketing authorization based on a 49-week study of 600 treatment-naive HIV-infected patients, Gilead said.

Back to other CDC news for May 28, 2003

Previous Updates

Adapted from:

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.